Neurex launches phase III program for SNX-111 for the treatment of chronic pain.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D010148:Intractable Pain / Q000188:drug therapy* / Q000209:etiology; D010455:Peptides / Q000627:therapeutic use*; D020960:omega-Conotoxins
D002121:Calcium Channel Blockers; D010455:Peptides; D020960:omega-Conotoxins; C078452:ziconotide